Loan

iRhythm Announces Proposed Offering of $450.0 Million of Convertible Senior Notes

Retrieved on: 
måndag, mars 4, 2024
SAN, Person, Research, Investment, Marketing, Sale, Exercise, Debt-to-GDP ratio, Loan, Observation, Convertible, IRTC, Public expenditure, Disease, Security, Credit, Security (finance)

The notes will be senior, unsecured obligations of iRhythm, and interest will be payable semi-annually in arrears.

Key Points: 
  • The notes will be senior, unsecured obligations of iRhythm, and interest will be payable semi-annually in arrears.
  • The notes will mature on September 1, 2029, unless earlier converted, repurchased or redeemed in accordance with the terms of the notes.
  • Upon conversion, the notes may be settled in shares of iRhythm’s common stock, cash or a combination of cash and shares of iRhythm’s common stock, at the election of iRhythm.
  • The interest rate, initial conversion rate, offering price and other terms are to be determined upon pricing of the notes.

KBRA Assigns a Preliminary Rating to BHG Securitization Trust 2024-1CON

Retrieved on: 
måndag, mars 4, 2024
Banking, Professional Services, Finance, Loan, ABS, Credit, BHG, BHG Financial, Consumer, KBRA, Telescopic sight

The preliminary rating reflects the initial credit enhancement level of 54.70% for the Class A notes.

Key Points: 
  • The preliminary rating reflects the initial credit enhancement level of 54.70% for the Class A notes.
  • BHG 2024-1 represents the ninth term ABS securitization for the Bankers Healthcare Group, LLC (“BHG” or the “Company”), but the first ABS securitization collateralized exclusively by Consumer Loans.
  • BHG was founded in 2001 and provides Commercial Loans and Consumer Loans primarily to prime, high income professionals.
  • KBRA considered its operational review of BHG, as well as periodic update calls with the Company.

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
onsdag, februari 28, 2024
Biotechnology, General Health, Pharmaceutical, Health, Janus, Hercules, BAT, European Commission, EMA, Marketing, Research, New Drug Application, Anemia, Transfusion-dependent anemia, Syndrome, MAA, MF, FDA, Geron Corporation, Imetelstat, Exercise, PDUFA, Loan, Risk, Primary myelofibrosis, Society, MDS, Civil service commission, JAK, History, European Medicines Agency, Webcast, Register, SVB, Patient, Federal, Clinical trial, Corporation, NDA, Depreciation

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.
  • The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 to the NDA.
  • In September 2023, the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for imetelstat in the same proposed indication as the NDA.
  • Geron will host a conference call at 8:00 am ET on Wednesday, February 28, 2024, to discuss business updates and fourth quarter and full year 2023 financial results.

Innovative Industrial Properties Reports Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
måndag, februari 26, 2024
REIT, Cannabis, Natural Resources, Commercial Building & Real Estate, Construction & Property, Acquisition, Collection, FFO, Loan agreement, LP, Total, Note, IIP, Investment, ATM, Renting, Debt-to-GDP ratio, Tenant, Loan, Letter, Line of credit, GAAP, Judgement, Pleasanton Unified School District, Webcast, Tax, Normalization, Vertical, Credit, Partnership, Property management

Issued shares of common stock under IIP’s “at-the-market” offering program (ATM Program) for net proceeds of approximately $9.6 million.

Key Points: 
  • Issued shares of common stock under IIP’s “at-the-market” offering program (ATM Program) for net proceeds of approximately $9.6 million.
  • Executed a new lease with a tenant at one of IIP’s retail properties in Michigan that was previously leased to Green Peak.
  • Industrial (cultivation and/or processing), retail (dispensing) and combined industrial/retail represent 92%, 2% and 6% of the operating portfolio, respectively.
  • Innovative Industrial Properties, Inc. will conduct a conference call and webcast at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) on Tuesday, February 27, 2024 to discuss IIP’s financial results and operations for the fourth quarter and year ended December 31, 2023.

IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company

Retrieved on: 
onsdag, februari 28, 2024
Regulation, Person, News, Canadian Securities Exchange, Sale, KDST, Par value, Diabetes, ALS, Term sheet, Biotechnology, Legacy, Loan, Spin-off (media), CVR, Loan agreement, IMCC, Transaction, Date, Holding company, FDA, Debtor, Executive, Tel Aviv Stock Exchange, Security (finance)

TORONTO and GLIL YAM, Israel, Feb. 28, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company" or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that it has entered into a non-binding term sheet dated February 13, 2024, as amended (the "Term Sheet"), and a Loan Agreement (as defined below) with Holding Company (as defined below), with Israel-based Kadimastem Ltd a clinical cell therapy public company traded on the Tel Aviv Stock Exchange under the symbol (TASE: KDST) ("Kadimastem"), whereby the parties will complete a business combination that will constitute a reverse merger into the Company by Kadimastem (the "Proposed Transaction").

Key Points: 
  • We have been looking for a way to deliver maximum value for our shareholders in the current situation and believe that a reverse merger with Kadimastem will provide this," said Oren Shuster, CEO of IMC.
  • "With its focus on clinical stage cell therapy, and an FDA approval for a Phase IIa clinical trial, we believe that Kadimastem has tremendous potential."
  • The Proposed Transaction will be effected by way of a plan of arrangement involving a newly created wholly-owned subsidiary of IMC and Kadimastem (the "Arrangement").
  • Pursuant to the terms of the Term Sheet, a loan agreement dated February 28, 2024 (the "Loan Agreement") was entered between IMC Holdings Ltd. a wholly-owned subsidiary of IMC (the "Holding Company") and Kadimastem.

Sirona Biochem Provides Update on Loan

Retrieved on: 
torsdag, februari 15, 2024
TSX Venture Exchange, OTC, News, Loan, Share (finance), Legislation, Creditor, Minority, Bank

VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp .

Key Points: 
  • VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp .
  • The Amended Note evidences a loan in the aggregate principal amount of up to $1,000,000 (the “Loan”).
  • The Company has drawn on the Loan in six installments from September 22, 2023, to December 29, 2023.
  • The current outstanding balance on the Loan is $540,000 and as of January 31, 2024, the accrued interest on the Loan was $11,178.08.

60th NPLA Conference Comes to Miami Beach, Florida, March 7-9

Retrieved on: 
torsdag, februari 15, 2024
Hornik, Research, Education, Loews Hotels, Learning, Private law, Conference, Hard Rock Cafe, Organization, Housing, Loan, LHR

MARLBORO, N.J., Feb. 15, 2024 /PRNewswire/ -- The NPLA Conference, the largest private lending conference in the country, is coming to Miami Beach on March 7-9, 2024.

Key Points: 
  • The private lending industry's premier event attracts nationwide leaders, including Private Lender Law and Private Lender Title
    MARLBORO, N.J., Feb. 15, 2024 /PRNewswire/ -- The NPLA Conference, the largest private lending conference in the country, is coming to Miami Beach on March 7-9, 2024.
  • The NPLA Conference is the largest private lending conference in the country.
  • Two of the nation's leading private lending organizations will be headlining at the National Private Lenders Association (NPLA) Conference : Private Lender Law and Private Lender Title.
  • The 60th NPLA Conference will take place from March 7 through 9, 2024, at the Loews Hotel in Miami Beach.

Finnvera Group’s Report of the Board of Directors and Financial Statements 2023

Retrieved on: 
torsdag, februari 15, 2024
XHTML, Investment, Growth, Business Finland, Loan, Government, Risk, SME, Climate, PDF, EUR, Fund, Negotiable instrument, Finnvera, Bank statement, Renewable energy

Finnvera was able to partially reverse loss provisions in 2023, particularly regarding the shipping sector.

Key Points: 
  • Finnvera was able to partially reverse loss provisions in 2023, particularly regarding the shipping sector.
  • Finnvera publishes its Board of Directors’ Report and its financial statements as an XHTML file compliant with the European Single Electronic Format (ESEF) requirements.
  • Auditors KPMG Oy have issued an independent assurance report that provides reasonable assurance concerning Finnvera’s ESEF financial statements.
  • Finnvera additionally publishes the report and financial statements in PDF format.

Myers Industries Completes Acquisition of Signature Systems

Retrieved on: 
torsdag, februari 8, 2024
General Automotive, Packaging, Retail, Engineering, Chemicals, Plastics, Manufacturing, Other Transport, Automotive, Transport, Other Retail, Other Automotive, Other Manufacturing, Tires & Rubber, Textiles, Honigman LLP, EPS, Wells Fargo, Acquisition, Investment, Growth, GAAP, JPMorgan Chase, Sater, J. P. Morgan, Loan

Myers Industries, Inc. (NYSE: MYE) (“Myers” or the “Company”), a leading manufacturer and distributor of industrial products, today announced that it has completed its acquisition of Signature Systems (“Signature”), which was previously announced on January 2, 2024.

Key Points: 
  • Myers Industries, Inc. (NYSE: MYE) (“Myers” or the “Company”), a leading manufacturer and distributor of industrial products, today announced that it has completed its acquisition of Signature Systems (“Signature”), which was previously announced on January 2, 2024.
  • “We are excited to welcome the Signature team to Myers with the closing of this transaction,” said Mike McGaugh, Chief Executive Officer of Myers Industries.
  • “This acquisition strengthens our growing portfolio of market leading brands, enhances our profitability profile and demonstrates Myers’ capability as a platform for acquisitive growth.
  • The financial results of Signature Systems are expected to be included within Myers’ Material Handling segment.

Candor Secures Series B Funding, Led by Rice Park Capital

Retrieved on: 
måndag, februari 5, 2024
Architecture, Other Construction & Property, Residential Building & Real Estate, Construction & Property, Urban Planning, Building Systems, Bank of America, Growth, Knowledge, JPMorgan Chase, CFO, Central Waqf Council, QC, Fifth Third Bank, Bank, Loan

The funding was led by Minneapolis-based Rice Park Capital Management, with the support of Arthur Ventures, Assurant Ventures and the management team; as well as participation from several other industry leaders.

Key Points: 
  • The funding was led by Minneapolis-based Rice Park Capital Management, with the support of Arthur Ventures, Assurant Ventures and the management team; as well as participation from several other industry leaders.
  • “We’re very excited to have joined the Rice Park family of companies,” said Mark Hinshaw, Candor’s newly appointed Chief Executive Officer.
  • “Rice Park brings unique synergies to Candor that extends far beyond its investment.
  • “We are excited to be an investor in Candor, to have led this Series B round, and to provide an active role on the board,” stated Chris Bixby, Managing Director of Strategic Equity Investing at Rice Park Capital.